The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review
Author
Abstract
Suggested Citation
DOI: 10.1007/s40258-018-0406-6
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Atanu Saha & Henry Grabowski & Howard Birnbaum & Paul Greenberg & Oded Bizan, 2006. "Generic Competition in the US Pharmaceutical Industry," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 13(1), pages 15-38.
- Lexchin, Joel, 2004. "The effect of generic competition on the price of brand-name drugs," Health Policy, Elsevier, vol. 68(1), pages 47-54, April.
- Henry G. Grabowski & David B. Ridley & Kevin A. Schulman, 2007. "Entry and competition in generic biologics," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 439-451.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Shiri Mermelstein & Hilde Stevens, 2022. "TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines," ULB Institutional Repository 2013/337220, ULB -- Universite Libre de Bruxelles.
- Kevin Kress & Sam Millet & Étienne Labussière & Ulrike Weiler & Volker Stefanski, 2019. "Sustainability of Pork Production with Immunocastration in Europe," Sustainability, MDPI, vol. 11(12), pages 1-20, June.
- Carmen-Pilar Martí-Ballester, 2020. "Financial Performance of SDG Mutual Funds Focused on Biotechnology and Healthcare Sectors," Sustainability, MDPI, vol. 12(5), pages 1-15, March.
- R. Brett McQueen & Kelly E. Anderson & Joseph F. Levy & Josh J. Carlson, 2023. "Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?," PharmacoEconomics, Springer, vol. 41(3), pages 321-327, March.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Roger Feldman & Félix Lobo, 2013. "Competition in prescription drug markets: the roles of trademarks, advertising, and generic names," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(4), pages 667-675, August.
- Sotiris Vandoros, 2014. "Therapeutic Substitution Post‐Patent Expiry: The Cases Of Ace Inhibitors And Proton Pump Inhibitors," Health Economics, John Wiley & Sons, Ltd., vol. 23(5), pages 621-630, May.
- Jorge Mestre-Ferrandiz & Adrian Towse & Mikel Berdud, 2016. "Biosimilars: How Can Payers Get Long-Term Savings?," PharmacoEconomics, Springer, vol. 34(6), pages 609-616, June.
- Merja Halme & Kari Linden & Kimmo Kääriä, 2009. "Patients’ Preferences for Generic and Branded Over-the-Counter Medicines," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 2(4), pages 243-255, December.
- Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022.
"Generic competition and the incentives for early-stage pharmaceutical innovation,"
Research Policy, Elsevier, vol. 51(10).
- Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2014. "Generic Competition and the Incentives for Early-Stage Pharmaceutical Innovation," NBER Working Papers 20532, National Bureau of Economic Research, Inc.
- Unsal, Omer & Houston, Reza, 2024. "R&D grants and medical innovation," Journal of Economics and Business, Elsevier, vol. 128(C).
- François Bocquet & Anaïs Loubière & Isabelle Fusier & Anne-Laure Cordonnier & Pascal Paubel, 2016. "Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience," PharmacoEconomics, Springer, vol. 34(11), pages 1173-1186, November.
- Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011.
"Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment,"
Journal of Public Economics, Elsevier, vol. 95(7), pages 624-638.
- Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011. "Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment," Journal of Public Economics, Elsevier, vol. 95(7-8), pages 624-638, August.
- Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume, 2010. "Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment," CESifo Working Paper Series 3258, CESifo.
- Joan Costa-i-Font & Alistair McGuire & Nebibe Varol, 2011.
"Does Pharmaceutical Price Regulation Affect the Adoption of Generic Competition? Evidence from the OECD, 1999-2008,"
CESifo Working Paper Series
3441, CESifo.
- Costa-i-Font, Joan & Varol, Nebibe & McGuire, Alistair, 2011. "Does pharmaceutical price regulation affect the adoption of generic competition?: evidence from the OECD, 1999-2008," LSE Research Online Documents on Economics 37537, London School of Economics and Political Science, LSE Library.
- Takizawa, Osamu & Urushihara, Hisashi & Tanaka, Shiro & Kawakami, Koji, 2015. "Price difference as a predictor of the selection between brand name and generic statins in Japan," Health Policy, Elsevier, vol. 119(5), pages 612-619.
- Melissa Newham & Jo Seldeslachts & Albert Banal-Estanol, 2018.
"Common ownership and market entry: Evidence from the pharmaceutical industry,"
Working Papers of Department of Management, Strategy and Innovation, Leuven
623896, KU Leuven, Faculty of Economics and Business (FEB), Department of Management, Strategy and Innovation, Leuven.
- Melissa Newham & Jo Seldeslachts & Albert Banal-Estanol, 2018. "Common Ownership and Market Entry: Evidence from Pharmaceutical Industry," Discussion Papers of DIW Berlin 1738, DIW Berlin, German Institute for Economic Research.
- Albert Banal-Estañol & Melissa Newham & Jo Seldeslachts, 2018. "Common Ownership and Market Entry: Evidence from the Pharmaceutical Industry," Working Papers 1042, Barcelona School of Economics.
- Melisa Newham & Jo Seldeslachts & Albert Banal-Estañol, 2018. "Common ownership and market entry: Evidence from the pharmaceutical industry," Economics Working Papers 1612, Department of Economics and Business, Universitat Pompeu Fabra.
- Newham, M. & Seldeslachts, J. & Banal-Estanol, A., 2018. "Common Ownership and Market Entry: Evidence from the Pharmaceutical Industry," Working Papers 18/03, Department of Economics, City University London.
- Serra-Sastre, Victoria & Bianchi, Simona & Mestre-Ferrandiz, Jorge & O’Neill, Phill, 2021. "Does NICE influence the adoption and uptake of generics in the UK?," LSE Research Online Documents on Economics 113639, London School of Economics and Political Science, LSE Library.
- Berndt, Ernst R. & Dubois, Pierre, 2012.
"Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010,"
IDEI Working Papers
702, Institut d'Économie Industrielle (IDEI), Toulouse.
- Berndt, Ernst R. & Dubois, Pierre, 2012. "Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010," TSE Working Papers 12-283, Toulouse School of Economics (TSE).
- Berndt, Ernst R & Dubois, Pierre, 2012. "Impacts of Patent Expiry and Regulatory Policies on Daily Cost of Pharmaceutical Treatments: OECD Countries, 2004-2010," CEPR Discussion Papers 9140, C.E.P.R. Discussion Papers.
- Fiona M. Scott Morton & Ariel Dora Stern & Scott Stern, 2018. "The Impact of the Entry of Biosimilars: Evidence from Europe," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 173-210, August.
- Timonen, Johanna & Karttunen, Pekka & Bengtström, Marina & Ahonen, Riitta, 2009. "The impact of generic substitution on the turnover and gross margin of pharmaceutical companies a survey 1 year and 5 years after the introduction of generic substitution in Finland," Health Policy, Elsevier, vol. 92(2-3), pages 116-123, October.
- Phill O’Neill & Jorge Mestre-Ferrandiz & Ruth Puig-Peiro & Jon Sussex, 2013. "Projecting Expenditure on Medicines in the UK NHS," PharmacoEconomics, Springer, vol. 31(10), pages 933-957, October.
- Bruce Rasmussen, 2010. "Innovation and Commercialisation in the Biopharmaceutical Industry," Books, Edward Elgar Publishing, number 13680.
- Atal, Juan Pablo & Cuesta, José Ignacio & Sæthre, Morten, 2018.
"Quality Regulation and Competition: Evidence from Pharmaceutical Markets,"
Discussion Paper Series in Economics
20/2018, Norwegian School of Economics, Department of Economics.
- Jesus Juan Pablo Atal & Jose´ Ignacio Cuesta & Morten Sæthre, 2019. "Quality Regulation and Competition: Evidence from Pharmaceutical Markets," PIER Working Paper Archive 19-017, Penn Institute for Economic Research, Department of Economics, University of Pennsylvania.
- Juan Pablo Atal & José Ignacio Cuesta & Morten Sæthre, 2022. "Quality Regulation and Competition: Evidence from Pharmaceutical Markets," NBER Working Papers 30325, National Bureau of Economic Research, Inc.
- Atal, Juan Pablo & Cuesta, Jose Ignacio & Sæthre, Morten, 2018. "Quality Regulation and Competition: Evidence from Pharmaceutical Markets," Research Department working papers 1211, CAF Development Bank Of Latinamerica.
- Panos Kanavos & Joan Costa Font & Alistair McGuire, 2007. "Product differentiation, competition and regulation of new drugs: the case of statins in four European countries," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 455-465.
- Ernst R. Berndt & Joseph P. Newhouse, 2010.
"Pricing and Reimbursement in U.S. Pharmaceutical Markets,"
NBER Working Papers
16297, National Bureau of Economic Research, Inc.
- Newhouse, Joseph Paul & Berndt, Ernst R., 2010. "Pricing and Reimbursement in U.S. Pharmaceutical Markets," Scholarly Articles 4450127, Harvard Kennedy School of Government.
- Berndt, Ernst R. & Newhouse, Joseph P., 2010. "Pricing and Reimbursement in U.S. Pharmaceutical Markets," Working Paper Series rwp10-039, Harvard University, John F. Kennedy School of Government.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:16:y:2018:i:5:d:10.1007_s40258-018-0406-6. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.